Sanofi invests $700M in Alnylam's RNAi tech; Merck drops RNAi specialist Sirna;

> Sanofi ($SNY) invested $700 million in Alnylam's ($ALNY) RNAi technology. Story

> Merck ($MRK) sold Sirna Therapeutics, its RNAi arm, to Alnylam ($ALNY). Article

> Researchers at the University of North Carolina have come up with a new way to visualize RNA, an advancement that could have future implications for drug delivery. More

> Interface Biologics and Q3 Medical Devices signed an agreement to develop a drug-coated balloon with Interface's Kinesyx technology. Release

Suggested Articles

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.